Bayer to Showcase Advanced Radiology Portfolio and Novel Contrast Agent at ECR 2025
Key Insights
Bayer will present pivotal Phase III data for gadoquatrane, its investigational low-dose contrast agent for MRI, demonstrating comparable efficacy to standard macrocyclic agents at 60% lower gadolinium dose.
The company introduces Centargo | Cardio, a comprehensive cardiac CT injection system package, and expands its AI capabilities through a new partnership with MIT spin-off Systalyze (search) on the AI Innovation Platform.
Bayer's radiology division, generating €2 billion in sales in 2023, continues to advance its portfolio across contrast media, injection systems, and AI-enabled solutions for improved patient care.
Bayer is set to unveil significant advances in its radiology portfolio at the upcoming European Congress of Radiology (ECR) 2025 in Vienna, with breakthrough developments in contrast agents, injection systems, and artificial intelligence solutions.
Breakthrough Data for Novel Contrast Agent
The spotlight will be on gadoquatrane, Bayer's investigational macrocyclic gadolinium-based contrast agent (GBCA) for magnetic resonance imaging (MRI). Late-breaking data from the QUANTI CNS Phase III study will showcase the agent's effectiveness at a reduced dose of 0.04 mmol Gd/kg body weight, compared to standard macrocyclic GBCAs at 0.1 mmol Gd/kg body weight. This represents a significant advancement in contrast agent technology, potentially offering comparable imaging quality with substantially reduced gadolinium exposure.
Advanced Cardiac Imaging Solutions
Bayer's commitment to cardiac imaging takes a leap forward with the introduction of Centargo | Cardio, an innovative injection system package for Cardiac CT. The system combines the MEDRAD Centargo CT Injection System with premium clinical application services and patient preparation resources, designed to enhance imaging quality and streamline workflow efficiency.
Expanding AI Capabilities in Radiology
In a strategic move to strengthen its digital offerings, Bayer announces a collaboration with Systalyze (search), a Massachusetts Institute of Technology spin-off, through its AI Innovation Platform (AIIP). Built on Google Cloud technology, the platform aims to accelerate the development and deployment of AI-enabled imaging solutions.
The company's Calantic Digital Solutions marketplace continues to gain traction, with successful implementations across European healthcare institutions, including:
- Inselspital Bern in Switzerland
- Imapôle medical imaging departments in France
- TéléDiag telemedicine network
- SERGAS Galician Health Service pilot program
Environmental and Efficiency Initiatives
Sustainability efforts are highlighted through a MEDRAD Centargo study conducted at the CIMROD (search) center in France, addressing contrast product consumption and environmental impact. The system, now available in 51 markets following recent FDA clearance, offers solutions for radiology departments facing staffing challenges and increasing imaging demands.
Research Pipeline and Clinical Evidence
Additional scientific presentations at ECR 2025 will cover:
- Preclinical data on a new macrocyclic MRI liver agent
- Long-term safety analysis of gadoxetate disodium across 12 million administrations
- Results from the DENSE-2 study on contrast-enhanced mammography
- Systematic review of AI applications in cardiovascular imaging
Building on its century-long heritage in radiology and €2 billion in sales for 2023, Bayer continues to strengthen its position as a leading provider of contrast media, administration devices, and digital solutions. The company's comprehensive approach combines innovative product development with practical solutions for healthcare providers, advancing toward more efficient and optimized patient care in radiology.